Except for cytotoxic chemotherapy and targeted therapy, immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) or PD-1 ligand (PD-L1) have emerged as promising treatment strategies in CRC that lead to durable antitumor activities and improved survival (42, 43). The gene discussed is PDCD1; the disease is colorectal carcinoma.